Stock Events

Stock Events

Reviva Pharmaceuticals 

$0.28
0
-$0.01-3.08% Today

Statistics

Day High
0.3
Day Low
0.28
52W High
-
52W Low
-
Volume
3,358
Avg. Volume
-
Mkt Cap
32.6M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

23MarExpected
Q3 2025
Next
-0.09
-0.08
-0.07
-0.05
Expected EPS
-0.054286
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-59.84MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RVPH.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap5.07B
Alkermes develops therapies for serious mental illness, overlapping with Reviva Pharmaceuticals' focus areas.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.83B
ACADIA Pharmaceuticals specializes in central nervous system disorders, including treatments for psychiatric conditions, competing with Reviva's product pipeline.
BridgeBio Pharma
BBIO
Mkt Cap12.07B
BridgeBio Pharma targets genetic diseases and cancers, some of which involve neurological components, indirectly competing with Reviva's neurological focus.
Insmed
INSM
Mkt Cap40.44B
Insmed incorporates novel approaches to treat serious and rare diseases, including lung and neurological conditions, making it a competitor.
Axsome Therapeutics
AXSM
Mkt Cap6.74B
Axsome Therapeutics works on central nervous system disorders, including depression and migraine, areas Reviva is also targeting.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurology, neurodegenerative diseases, and multiple sclerosis, areas that overlap with Reviva's interests in neurological disorders.
AMGEN
AMGN
Mkt Cap160.66B
Amgen, with a broader focus, has ventured into neuroscience, including treatments for migraine, which could compete with Reviva's neurological drug development.

About

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
Show more...
CEO
Dr. Laxminarayan Bhat Ph.D.
Employees
14
Country
US
ISIN
US76152G1004

Listings

XNAS
US
RVPH
BOATS
BOATS
RVPH.BOATS

0 Comments

Share your thoughts

FAQ

What is Reviva Pharmaceuticals stock price today?▼
The current price of RVPH.BOATS is $0.28 USD — it has decreased by -3.08% in the past 24 hours. Watch Reviva Pharmaceuticals stock price performance more closely on the chart.
What is Reviva Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Reviva Pharmaceuticals stocks are traded under the ticker RVPH.BOATS.
What is Reviva Pharmaceuticals market cap?▼
Today Reviva Pharmaceuticals has the market capitalization of 32.6M
When is the next Reviva Pharmaceuticals earnings date?▼
Reviva Pharmaceuticals is going to release the next earnings report on March 23, 2026.
What were Reviva Pharmaceuticals earnings last quarter?▼
RVPH.BOATS earnings for the last quarter are -0.06 USD per share, whereas the estimation was -0.09 USD resulting in a +36.66% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Reviva Pharmaceuticals revenue for the last year?▼
Reviva Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Reviva Pharmaceuticals net income for the last year?▼
RVPH.BOATS net income for the last year is -59.84M USD.
How many employees does Reviva Pharmaceuticals have?▼
As of February 03, 2026, the company has 14 employees.
In which sector is Reviva Pharmaceuticals located?▼
Reviva Pharmaceuticals operates in the Health Care sector.
When did Reviva Pharmaceuticals complete a stock split?▼
Reviva Pharmaceuticals has not had any recent stock splits.
Where is Reviva Pharmaceuticals headquartered?▼
Reviva Pharmaceuticals is headquartered in Cupertino, US.